Comparative Pharmacology
Head-to-head clinical analysis: CORTIFOAM versus SOLU CORTEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTIFOAM versus SOLU CORTEF.
CORTIFOAM vs SOLU-CORTEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cortifoam (hydrocortisone acetate) is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses immune cell migration and cytokine release.
Solu-Cortef (hydrocortisone sodium succinate) is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators, including prostaglandins and leukotrienes. It also inhibits immune cell migration and activation.
1 applicatorful (90 mg hydrocortisone acetate) rectally twice daily for 2-3 weeks, then every other day as needed.
100-1000 mg intravenous (IV) or intramuscular (IM), then 100-500 mg IV or IM every 2-6 hours as needed.
None Documented
None Documented
Approximately 1.5-2 hours for hydrocortisone; clinically, effects persist longer due to local action.
Terminal elimination half-life: 1.5-2 hours (hydrocortisone); clinical duration of action is longer due to genomic effects (6-8 hours).
Primarily renal (about 70-90% as metabolites) and fecal (about 10-30% as metabolites).
Renal: ~80% as metabolites (mainly 17-hydroxycorticosteroids) and <5% unchanged. Biliary/fecal: minimal (<5%).
Category C
Category C
Corticosteroid
Corticosteroid